-
|
GlobeNewswire –
4:59 PM ET 01/05/2021
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that the Compensation Committee of its Board of Directors granted a stock option to purchase 115,000 shares of its common stock to a new employee, pursuant to the Cidara Therapeutics, Inc. (CDTX) 2020 I...
|
-
|
GlobeNewswire –
8:00 AM ET 12/15/2020
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointment of Christopher Kurtz as executive vice president of technical operations.
|
-
|
GlobeNewswire –
8:00 AM ET 12/01/2020
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced a keynote lecture, an oral presentation and two posters at the 7th European Scientific Working Group on Influenza Influenza Conference, which takes place virtually Dec. 6-9, 2020.
|
-
|
GlobeNewswire –
8:00 AM ET 11/30/2020
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present three posters at European Society of Intensive Care Medicine LIVES 2020, which takes place virtually Dec. 6-9, 2020.
|
-
|
GlobeNewswire –
8:00 AM ET 11/16/2020
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the fourth consecutive year.
|
-
|
GlobeNewswire –
4:05 PM ET 11/11/2020
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two upcoming conferences: the Stifel 2020 Virtual Healthcare Conference and 3rd Annual Evercore ISI HealthCON...
|
-
|
Reuters –
4:56 PM ET 11/05/2020
Cidara Therapeutics Inc (CDTX): * CIDARA PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS. * NOW ANTICIPATE TOP-LINE DATA FROM RESTORE TRIAL BY END OF 2021. * CASH, CASH EQUIVALENTS AND RESTRICTED CASH TOTALED $53.7 MILLION AS OF SEPTEMBER 30, 2020. * QTRLY TOTAL REVENUES $2.4 MILLION VERSUS $19.1 MILLION.
|
-
|
GlobeNewswire –
4:24 PM ET 11/05/2020
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended September 30, 2020, and provided an update on its corporate activities.
|
-
|
Reuters –
8:24 AM ET 10/21/2020
Cidara Therapeutics Inc (CDTX): * CIDARA THERAPEUTICS ANNOUNCES NEW CLINICAL AND PRECLINICAL DATA FOR REZAFUNGIN AND INFLUENZA AVCS AT IDWEEK 2020 Source text for Eikon: Further company coverage:
|
-
|
GlobeNewswire –
8:00 AM ET 10/21/2020
Presentations highlight clinical and preclinical progress of long-acting drug candidates for serious fungal and viral infections Posters presenting new analyses from completed Phase 2 STRIVE trial support the efficacy and pharmacokinetics of once-weekly rezafungin in the treatment of candidemia and invasive candidiasis Oral and poster presentations highlight potential of antiviral conjugates fo...
|
-
|
GlobeNewswire –
8:00 AM ET 10/13/2020
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two posters at the 2020 American College of Clinical Pharmacy Annual Meeting, which takes place virtually from October 19-30, 2020.
|
-
|
GlobeNewswire –
8:00 AM ET 09/14/2020
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two oral abstracts and seven posters at IDWeek 2020, the joint annual meeting of the Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, t...
|
-
|
GlobeNewswire –
8:00 AM ET 09/02/2020
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in four investor conferences in September: Citis 15th Annual BioPharma Conference, H.C. Wainwright 22nd Annual Global In...
|
-
|
GlobeNewswire –
4:48 PM ET 08/13/2020
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended June 30, 2020, and provided an update on its corporate activities and product pipeline.
|
-
|
GlobeNewswire –
8:00 AM ET 08/04/2020
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020.
|
-
|
GlobeNewswire –
8:00 AM ET 07/27/2020
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced the formation of a scientific advisory board and the appointment of four leading experts in viral and fungal infections and hematology.
|
Page:
|
Today's and Upcoming Events
-
CDTX to announce Q4 earnings (Unconfirmed)
Past Events (last 90 days)
-
CDTX announced Q3 earnings.
Data provided by Thomson Reuters © 2021
|